Nuclear medicine vendor Digirad of Poway, CA, has begun clinical trials for a new imaging module designed to correct image distortion in cardiac SPECT imaging.
Initial clinical trials for Cardius X-ACT will take place at the University of California, Los Angeles (UCLA) to improve imaging clarity and accuracy and reduce imaging time and radiation dose.
Two other clinical studies are planned for the system, which is based on Digirad's Cardius 3 triple-head SPECT camera.
Digirad hopes to market Cardius X-ACT sometime next year after receiving regulatory clearance.
Related Reading
Novel cardiac SPECT system improves attenuation correction, August 15, 2008
Digirad posts loss in Q2, July 29, 2008
Digirad signs deal with U. of Chicago, April 29, 2008
Digirad Q1 results dip into red, April 24, 2008
Digirad fined by NRC, April 8, 2008
Copyright © 2008 AuntMinnie.com
